Views
3 years ago

Manual de hipertensión arterial - Sección 10 anexo

  • Text
  • Secundaria
  • Hta
  • Consultorio
  • Presion
  • Anexo
  • Pacientes
  • Clinical
  • Debe
  • Secundaria
  • Cardiovascular
  • Renal
  • Obesidad
  • Clin
  • Hypertension
  • Arterial

Lecturas recomendadas of

Lecturas recomendadas of Hypertension (ESH). Nephrol Dial Transplant. 2017;32:620-40. — Vicenti F, Armend W, Abele J. The role of hypertension in hemodialysis associated atherosclerosis. Am Journal Med. 1980;68:365-9. Hipertensión renovascular — ASTRAL Investigators, Wheatley K, Ives N, et al. Revascularization versus Medical Therapy for Renal Artery Stenosis. N Eng J Med. 2009;361:1953-62. — Cheung CM, Hegarty J, Kalra PA. Dilemmas in the management of renal artery stenosis. Br Med Bull. 2005;73:35-55. — Cheung CM, Wright JR, Shurrab AE, et al. Epidemiology of renal dysfunction and patient outcome in atherosclerotic renal artery occlusion. J Am Soc Nephrol. 2002;13:149-57. — Hackam DG, Duong-Hua ML, Mamdani M, et al. Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J. 2008;156:549-55. — Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation. 2006;113:463-5 — Kotliar C, Juncos L, Inserra F, et al. Local and systemic cellular immunity in early renal artery atherosclerosis. Clin J Am Soc Nephrol. 2012;7(2):224-30. — Mitsuzaki K, Yamashita Y, Sakaguchi T, et al. Abdomen, pelvis, and extremities: diagnostic accuracy of dynamic contrast-enhanced turbo MR angiography compared with conventional angiography-initial experience. Radiology. 2000;216:909-15. — Ramos F, Kotliar C, Alvarez D, et al. Renal function outcome of PTRA and stenting for atherosclerotic renal artery stenosis. Kidney Int. 2003;63:276-82. — Textor SC. Renal failure related to ACE inhibitors. Semin Nephrol. 1997;17:67-76. — Vasbinder GB, Nelemans PJ, Kessels AG, et al. Renal Artery Diagnostic Imaging Study in Hypertension (RADISH) Study Group. Accuracy of computed tomographic angiography and magnetic resonance angiography for diagnosing renal artery stenosis. Ann Intern Med. 2004;141:674-82. SECCIÓN 4. Causas monogénicas y hereditarias-genéticas. Causas congénitas Hipertensión arterial con renina baja — Ahn SY, Gupta C. Genetic Programing of Hypertension. Front Pediatr. 2018;5:285. — Duan L, Shen R, Song L, et al. A novel chimeric CYP11B2/CYP11B1 combined with a new p.L340P CYP11B1 mutation in patient with 11OHD: case report. BMC Endocr Disord. 2018;18(1):23. — Ingelfinger JR. Monogenic and polygenic contributions to Hypertension. En Flynn J, Ingelfinger J, Portman R, editores. Pediatric Hypertension. Nueva Jersey: Humana Press; 2013, pp. 83-101. — Tetti M, Monticone S, Burrello J, et al. Liddle Syndrome: Review of the Literature and Description of a New Case. Int J Mol Sci. 2018;19(3). pii: E812. Enfermedad de Fabry — Germain D. Fabry disease. Review. Orphanet J Rare Dis. 2010;5:30. — Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular Events in Patients with Fabry Disease. Natural History Data From the Fabry Registry. JACC. 2011;57(9):1093-9. — Seydelmann N, Wanner C, Störk S, et al. Fabry disease and the heart. Best Pract Res Clin Endocrinol Metab. 2015;29(2):195-204. — Waldek S, Patel MR, Benikazemi M, et al. Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry. Genet Med. 2009;11(11):790-6. — Wilcox WR, Oliveira JP, Hopkin RJ, et al.; Fabry Registry. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93:112-28. Coartación de aorta — Alpert BS, Bain HH, Balfe JW, et al. Role of the reninangiotensin-aldosterone system in hypertensive children with coarctation of the aorta. Am J Cardiol. 1979;43:828-34. — Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults. First of two parts. N Engl J Med. 2000;342:256- 63. — Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-26. — Cook SC, Hickey J, Maul TM, et al. Assessment of the cerebral circulation in adults with coarctation of the aorta. Congenit Heart Dis. 2013;8:289-95. — Feltes TF, Bacha E, Beekman RH III, et al.; American Heart Association Congenital Cardiac Defects Committee of the Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; Council on Cardiovascular Radiology and Intervention. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation. 2011;123: 2607-52. — Greenberg SB, Balsara RK, Faerber EN. Coarctation of the aorta: diagnostic imaging after corrective surgery. J Thorac Imag. 1995;10:36-42. — Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890-900. — Allen HD, Shaddy RE, Penny DJ, et al. Moss & Adams’ Heart Disease in Infants, Children, and Adolescents, Including the Fetus and Young Adult. 9.ª ed. Lippincott Williams & Wilkins; 2016. — Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;73(12):1494- 563. — Teien DE, Wendel H, Björnebrink J, Ekelund L. Evaluation of anatomical obstruction by Doppler echocardiography and magnetic resonance imaging in patients with coarctation of the aorta. Br Heart J. 1993;69:352-5. SECCIÓN 5. Causas neurológicas Hipertensión neurogénica y perioperatoria — Hausberg M, Grassi G. Mechanisms of sympathetic overactivity in patients with chronic renal failure: a role for chemoreflex activation? J Hypertens. 2007;25(1):47-9. — Hering D, Marusic P, Walton AS, et al. Sustained sympathetic and blood pressure reduction 1 year after renal denervation in patients with resistant hypertension. Hypertension. 2014;64(1):118-24. — Hering D, Schlaich M. The role of central nervous system mechanisms in resistant hypertension. Curr Hypertens Rep. 2015;17(8):58. — Mann SJ. The clinical spectrum of labile hypertension: a management dilemma. J Clin Hypertens (Greenwich). 2009;11(9):491-7. — Mann SJ. Neurogenic hypertension: pathophysiology, diagnosis and management. Clin Auton Res. 2018;28(4):363-74. — Marques FZ, Morris BJ. Neurogenic hypertension: revelations from genomewide gene expression profiling. Curr Hypertens Rep. 2012;14(6):485-91. — Meng L, Yu W, Wang T, et al. Blood Pressure Targets in Perioperative Care. Provisional Considerations Based on a Comprehensive Literature Review. Hypertension. 2018;72:806-17. Disautonomías — Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264:1567-82. — Low P, Sandroni P, Benarroch E. Clinical autonomic disorders: classification and clinical evaluation. En Low P, Benarroch E, editores. Clinical Autonomic Disorders. 3.ª ed. Baltimore: Lippincott-Williams & Wilkins; 2008. — Milazzo V, Di Stefano C, Milan A, et al. Cardiovascular complications in patients with autonomic failure. Clin Auton Res. 2015;25:133-40. — Naschitz JE, Slobodin G, Elias N, et al. The patient with supine hypertension and orthostatic hypotension: a clinical dilemma. Postgrad Med J. 2006;82:246-53. — Ramirez AJ. Sistema 220 —

Lecturas recomendadas nervioso autónomo y control de la presión arterial. Rev Arg Anest. 2003;61:355- 9. — Sequeira Quesada CM, Casares Fallas DA. La hipertensión arterial supina en pacientes con desórdenes autonómicos: revisión anatómica y conceptual. Rev Clín Esc Med. 2018;8(1):11-20. — Vallelonga F, Maule S. Diagnostic and therapeutical management of supine hypertension in autonomic failure: a review of the literature. J Hypertens. 2018;36:1-10. Hipertensión endocraneana — Abbasi HN, Brady AJ, Cooper SA. Fulminant Idiopathic Intracranial Hypertension with Malignant Systemic Hypertension-A case report. Neuroophthalmology. 2013;37(3):120-3. — Chan KH, Mak W, Lo SL. Cryptococcal meningitis with raised intracranial pressure masquerading as malignant hypertension. Int J Infect Dis. 2007;11(4):366-7. — Iencean SM, Ciurea AV. Intracranial hypertension: classification and patterns of evolution. J Med Life. 2008;1(2):101-7. — Kaiser AM, Whitelaw GL. Hypertensive response to raised intracranial pressure in infancy. Arch Dis Child. 1988;63:1461-5. — Ogihara T, Matsuoka H, Kikuchi K, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH2009) Chapter 12. Secondary Hypertension. Hypertens Res. 2009;32:78-90. SECCIÓN 6. Causas respiratorias Síndrome de apneas e hipopneas obstructivas durante el sueño — Duran J, Esnaola S, Rubio R, et al. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 yr. Am J Respir Crit Care Med. 2001;163:685-9. — Eckert DJ, White DP, Jordan AS, et al. Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. Am J Respir Crit Care Med. 2013;188(8):996-1004. — González Mangado N, Egea Santaolalla C, Chiner Vives E, et al. Síndrome de apnea-hipopnea del sueño. Monogr Arch Bronconeumol. 2015;2(5):156-77. — Javaheri S, Barbe F, Campos-Rodriguez F, et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. J Am Coll Cardiol. 2017;69(7):841-58. — Lloberes P, Durán-Cantolla J, Martínez-García MA, et al. Diagnóstico y tratamiento del síndrome de apneas-hipopneas del sueño. Arch Bronconeumol. 2011;47:143-56. — Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet (London, England). 2005;365(9464):1046-53. — Nogueira F, Borsini E, Cambursano H, et al. Guías prácticas de diagnóstico y tratamiento del síndrome de apneas e hipopneas obstructivas del sueño: Actualización 2019. Rev Am Med Respir. 2019;19(1). — Nogueira F, Nigro C, Cambursano H, et al. Practical guidelines for the diagnosis and treatment of obstructive sleep apnea syndrome. Medicina (Buenos Aires). 2013;73(4):349-62. — Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811-7. — Tufik S, Santos-Silva R, Taddei JA, et al. Obstructive sleep apnea syndrome in the Sao Paulo Epidemiologic Sleep Study. Sleep Med. 2010;11(5):441-6. — Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middleaged adults. N Engl J Med. 1993;328:1230-5. SECCIÓN 7. Sustancias presoras Suplementos nutricionales — Colalto C. Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment. Pharmacol Res. 2010;62(3):207-27. — Agrawal M, Nandini D, Sharma V, et al. Herbal remedies for treatment of hypertension. Int J Pharm Sci Res. 2010;1:1-21. — Tres JC. Interacción entre fármacos y plantas medicinales. An Sist Sanit Navar. 2006;29(2):233-52. — Tachjian A, Viqar M, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol. 2010;55(6):515-25. — Umar A, Imam G, Yimin W, et al. Antihypertensive effects of Ocimum basilicum L. (OBL) on blood pressure in renovascular hypertensive rats. Hypertens Res. 2010;33(7):727-30. — Valli G, Giardina EG. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol. 2002;39(7):1083-95. — Veiga, VF, Pinto AC, Maciel MA. Plantas medicinais: cura segura? Quim Nova. 2005;28(3):519-28. — Xiong XJ, Liu W, Yang XC, et al. Ginkgo biloba extract for essential hypertension: a systemic review. Phytomedicine. 2014;21(10):1131-6. — World Health Organization. WHO monographs on selected medicinal plants. 1.ª ed. Ginebra: La Organización; 1999. Sal — Allen NB, Zhao L, Loria CM, et al. The Validity of Predictive Equations to Estimate 24-Hour Sodium Excretion. The MESA and CARDIA Urinary Sodium Study. Am J Epidemiol. 2017;186(2):149-59. — D’Elia L, Galletti F, La Fata E, et al. Effect of dietary sodium restriction on arterial stiffness: systematic review and meta-analysis of the randomized controlled trials. J Hypertens. 2017;36(4):734- 43. — Feng JH, MacGregor GA. Role of salt intake in prevention of cardiovascular disease: controversies and challenges. Nat Rev Cardiol. 2018;15:371-7. — George J, Majeed W, Mackenzie IS, et al. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested casecontrol study. BMJ. 2013; DOI:10.1136/bmj.f6954. — Institute of Medicine (U.S.). Panel on Dietary Reference Intakes for Electrolytes and Water. Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. Washington, DC: National Academies Press; 2005 [citada el 12 de diciembre de 2016]. Disponible en https://www.nap.edu/read/10925/chapter/1. — Kawamura M, Kusano Y, Takahashi T, et al. Effectiveness of a spot urine method in evaluating daily salt intake in hypertensive patients taking oral antihypertensive drugs. Hypertens Res. 2006;29(6):397-402. — Kurtz TW, DiCarlo SE, Pravenec M, et al. The American Heart Association Scientific Statement on salt sensitivity of blood pressure: prompting consideration of alternative frameworks for the pathogenesis of salt sensitivity? J Hypertens. 2017;35:221425. — Lerchl K, Rakova N, Dahlmann A, et al. Agreement between 24-hour salt ingestion and sodium excretion in a controlled environment. Hypertension. 2015;66:850-7. — Weinberger MH, Fineberg NS, Fineberg SE, et al. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001;37:429-32. Fármacos inmunosupresores, quimioterápicos y antiangiogénicos — Borrego C. Interacción de fármacos e hipertensión arterial. En Esper R, Kotliar C, Barontini M, Forcada P, editores. Tratado de Mecánica Vascular e Hipertensión Arterial. 1.ª ed. Buenos Aires: Intermédica; 2010, pp. 1023-26. — Cadenas N. Tendencia en el consumo de sustancias psicoactivas en Argentina. 2004 – 2010 Población de 16 a 65 años. En Boletín del Área de Investigaciones, junio de 2011. Secretaría de Programación para la Prevención de la Drogadicción y Lucha contra el Narcotráfico, SEDRONAR. Disponible en https://www.observatorio.gov. ar/investigaciones. — Grossman E, Messerli F, Grossman E. Drug-Induced Hypertension; an Unappreciated Cause of Secondary Hypertension. Am J Med. 2012;125:14-22. — Keown P, Kahan B, Johnston A, et al. Optimization of Cyclosporine Therapy With New Therapeutic Drug Monitoring Strategies: Report From the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). Transplant Proc. 1998;30:1645-9. — Saint-Marcoux F, Woillard J, Jurado C, et al. Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. Ther Drug Monit. 2013;35:322-7. Manual de hipertensión arterial secundaria — 221

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015